Arzneimittelwerk Dresden Gmbh

Andreas Stark

Hildegard Poppe

Reni Bartsch

Dieter Lohmann

Valentin V Lyskovzev

Helmut Wunderlich

Natalja V Kaverina

Aleksandr P Skoldinov

Anna N Grizenko

Lothar Zenker

Lothar Zenkar

Ekaterina K Grigoreva

New 3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines of formula I and their pharmaceutically acceptable salts were found to be suitable actives for the treatment of cardiac arrhythmia. Previously unknown 3-carbalkoxyamino-5-(alpha-halogenpropionyl)-5H-dibenz[b,f]azepines are obtained from 3-carbalkoxyamino-5H-dibenz[b,f]azepines by reaction with alpha-halogenpropionyl halides. Through their reaction with ammonia, primary amines or secondary amines, the new 3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines are obtained, which can be optionally converted into their pharmaceutically acceptable acid addition salts.

3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines and

New 3-carbalkoxyamino-5-aminoacyl-5H-dibenz[b,f]azepines and their pharmaceutically acceptable acid addition salts, and methods for their synthesis are described. These compounds are useful as antiarrhythmic agents in the treatment of heart disorders. The new compounds are made by reacting a 3-carbalkoxyamino-5-halogenacyl-5H-dibenz[b,f]azepines with an amine to form the desired target product, which can be optionally converted into its pharmaceutically acceptable acid addition salt.

3-carbalkoxyamino-5-aminoacyl-5H-dibenz[b,f]azepines, and methods for

Growing community of inventors

Radebeul, Germany

Andreas Stark